Pfizer: The Storm Has Passed -- Tailwinds Ahead

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.
Investor's Business Daily on MSN

Pfizer Hikes Earnings Outlook Even As Third-Quarter Sales Decline

Pfizer stock dipped early Tuesday despite hiking its 2025 profit guidance, as third-quarter sales and earnings both toppled ...

Why Pfizer's 7%-Yielding Dividend Just Became Safer -- and More Tempting

The greater a company's earnings, the better its position will be to pay dividends. However, Pfizer's adjusted earnings per ...

Pfizer's Slow Burn Comeback

Pfizer offers a 7% dividend yield, lower COVID sales, oncology and cardiometabolic focus, and growth from Metsera and ...

Pfizer & Novo boost Metsera bids, Hertz stock skyrockets

Market Catalysts host Julie Hyman takes a closer look at some of the trending tickers during Tuesday's trading session.

Is It Time to Dump Your Shares of Pfizer?

Pfizer also has set its sights on becoming a giant in oncology, and to support this, completed the acquisition of Seagen in 2023. Two of Seagen's products in the most recent quarter delivered ...

Stock Market News From Nov. 5, 2025: S&P 500 Rises After Supreme Court Tariff Hearing

The Dow, S&P 500, and Nasdaq rose Wednesday as the stock market weighed the Supreme Court's hearing on Trump tariffs.